Hypertension

Preclinical
Phase 1
Phase 2
Phase 3

brightn
cinrx_pipeline-artwork_heart
  • Treatment-Resistant Hypertension is defined as a high blood pressure that does not respond well to aggressive medical treatment.
  • Read about our Phase 2 interventional clinical trial, brigHtn, currently enrolling : A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Group, Dose-Ranging Study to Evaluate the Efficacy and Safety of 3 Doses of CIN-107 as Compared to Placebo After 12 Weeks of Treatment in Patients With Treatment-Resistant Hypertension (ClinicalTrials.gov ID: NCT04519658)
  • Study Enrollment Completed

Halo logo
hypertension
  • Uncontrolled Hypertension is defined as high blood pressure that is inadequately treated.
  • Read about our Phase 2 interventional clinical trial, HALO, currently enrolling : A Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Multiple Dose Strengths of CIN-107 as Compared to Placebo After 8 Weeks of Treatment in Patients with Uncontrolled Hypertension Receiving 1 Antihypertensive Agent (ClinicalTrials.gov ID: NCT05137002)
  • HALO Study will be followed by a long-term extension study to investigate the safety of CIN-107 over one year of treatment.
  • Study Enrollment

 
 
 
 
 
  • Chronic kidney disease (CKD) is defined by a gradual loss of kidney function, which can ultimately lead to kidney failure if left untreated. CKD and hypertension are often associated : declines in kidney function are typically associated with rises in blood pressure, and elevated blood pressure hastens the progression of kidney function decline. Besides its effects on blood pressure, too much aldosterone also has detrimental effects on kidney function through additional mode of actions.
  • Our Phase 2 interventional study in CKD patients is being planned for an early 2022 start date.

Primary Aldosteronism

Preclinical
Phase 1
Phase 2
Phase 3

Spark logo
  • Primary aldosteronism is a condition that occurs when the adrenal glands, two small glands located on the top of the kidneys, produce too much of aldosterone.
  • Read about our Phase 2 interventional clinical trial, Spark-PA, currently enrolling : A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Group, Dose-Ranging Study to Evaluate the Efficacy and Safety of CIN-107 for the Treatment of Patients With Primary Aldosteronism (ClinicalTrials.gov ID: NCT04605549)
  • Study Enrollment

ARTICLES AND PUBLICATIONS

For Hypertension and Primary Aldosteronism

  1. Preclinical and Early Clinical Profile of a Highly Selective and Potent Oral Inhibitor of Aldosterone Synthase (CYP11B2)
  2. Trends in Blood Pressure Control Among US Adults With Hypertension, 1999-2000 to 2017-2018
  3. The Unrecognized Prevalence of Primary Aldosteronism: A Cross-sectional Study
  4. Treatment of Resistant and Refractory Hypertension
  5. Hypertension Indication: Drug Labeling for Cardiovascular Outcome Claims JANUARY 2020
  6. Hypertension: Conducting Studies of Drugs to Treat Patients on a Background of Multiple Antihypertensive Drugs Guidance for Industry JULY 2018
  7. SPRINT Study (Systolic Blood Pressure Intervention Trial)
  8. A Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines
  9. Primary Aldosteronism: Three Strikes and Out. Hypertension
  10. Cardiometabolic outcomes and mortality in medically treated primary aldosteronism: a retrospective cohort study
  11. Aldosteronism and Hypertension
  12. Global Disparities of Hypertension Prevalence and Control: A Systematic Analysis of Population-Based Studies From 90 Countries
  13. Blood pressure is the most important cause of death and disability in the world
  14. Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies
  15. Final Report of a Trial of Intensive versus Standard Blood-Pressure Control
  16. Resistant hypertension-defining the scope of the problem
  17. Magnitude  of  Blood  Pressure  Reduction  in  the  Placebo   Arms  of  Modern  Hypertension  Trials